Autopsy report · NCT03473496

CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“After CAR-T treatment, the benefit is not significant, and it is difficult to enroll.”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 1 year 11 months before it stopped.
2 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Na
Sponsor: Zhujiang Hospital
Sponsor type: University, hospital or other
Conditions: Relapsed/Refractory Multiple Myeloma(MM)
Interventions: CART therapy in Relapsed/Refractory multiple myeloma
Participants: 2
Sites: 1
Countries: China

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.